Systematic evaluation and Meta-analysis of the efficacy and safety of different doses of tigecycline in ventilator-associated pneumonia caused by multiple resistant bacteria

Changwen Feng, Xiaoshan Yang, Junlin Lu, Qingming Mo, Zhaoxu Cai, Wendian Zhu2023 · DOI

Ventilator-associated pneumonia (VAP) is a critical complication in intensive care units (ICUs), significantly contributing to patient morbidity and mortality. The emergence of multi-drug resistant (MDR) bacteria has further complicated treatment, often leaving tigecycline as a "last-resort" antibiotic. However, clinical consensus on the optimal dosing of tigecycline remains elusive. This paper presents a protocol for a systematic review and meta-analysis designed to evaluate the efficacy and safety of various tigecycline dosing regimens in patients with VAP caused by MDR bacteria.

The Challenge of Resistant VAP

VAP caused by MDR pathogens presents a formidable challenge to standard antibiotic protocols. While tigecycline is effective against many resistant strains, its clinical application is hindered by a lack of standardized dosing guidelines. Higher doses may improve bacterial clearance but are frequently associated with increased adverse effects, such as gastrointestinal distress and liver toxicity. This study aims to synthesize existing evidence from randomized controlled trials (RCTs) to provide a clearer framework for balancing treatment efficacy with patient safety.

Methodology

The study follows a rigorous systematic review and meta-analysis (SRMA) framework:

  • Search Strategy: To minimize language bias and capture a global perspective, the researchers searched both Western databases (PubMed, Embase, Cochrane) and major Chinese databases (CNKI, Wanfang, Chinese Biomedical Literature). This is crucial as many clinical trials for MDR treatments are conducted in regions with high resistance rates, such as China.
  • Study Selection: The review is restricted to RCTs involving VAP patients treated with tigecycline for MDR infections. By limiting the review to RCTs and excluding case reports, the authors aim for Level 1 clinical evidence.
  • Quality Assessment: Methodological quality is assessed using the modified Jadad scale, focusing on randomization, blinding, and withdrawal reporting.
  • Statistical Analysis: Data synthesis is performed using Stata software. Heterogeneity is assessed via Cochran’s Q and the $I^2$ statistic. A fixed-effect model is employed if $I^2 < 50\%$; otherwise, a random-effects model is used to account for study variations.

Preliminary Insights

As this is a study protocol, final results are pending. However, preliminary analysis of six initial articles provides early insights into the safety-efficacy balance:

  • Safety Profile: The initial Odds Ratio (OR) for adverse effects was 0.96 (95% CI: 0.61–1.50, P=0.85), suggesting no statistically significant difference in side-effect frequency between dosing groups in the preliminary sample.
  • Heterogeneity: An $I^2$ of 51% was observed, indicating moderate variation between studies, which justified the use of a fixed-effect model for that specific subset.
  • Bias Assessment: Preliminary Egger’s tests and funnel plots indicated no significant publication bias regarding efficacy or safety indicators in the initial set of articles.

Limitations and Future Outlook

The current protocol does not yet detail subgroup or sensitivity analyses, which may be necessary if final results show high heterogeneity across different patient demographics or bacterial strains. Additionally, while RCTs provide high-quality data, they may not fully reflect "salvage therapy" scenarios common in real-world ICU practice.

Upon completion, this meta-analysis is expected to offer evidence-based dosing recommendations to optimize the use of tigecycline, helping clinicians maximize bacterial clearance while minimizing the incidence of adverse events in high-stakes clinical settings.

Summary updated

Abstract

Review question / Objective: Based on the Meta-analysis of the efficacy and safety of different doses
BibTeX
@misc{feng2023systematic,
  author = {Changwen Feng and Xiaoshan Yang and Junlin Lu and Qingming Mo and Zhaoxu Cai and Wendian Zhu},
  title = {{Systematic evaluation and Meta-analysis of the efficacy and safety of different doses of tigecycline in ventilator-associated pneumonia caused by multiple resistant bacteria}},
  year = {2023},
  doi = {10.37766/inplasy2023.4.0034},
}
Figure